1 / 34

Heart Test Laboratories Inc.

MyoVista™. Heart Test Laboratories Inc. About Heart test Laboratories. HTL is a Texas based Company HTL was established in 2007 HTL has developed and released its“patent pending” MyoVista™, a portable diagnostic device for the screening of Myocardial Ischemia (MI). About Beaufort Medical.

more
Download Presentation

Heart Test Laboratories Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MyoVista™ Heart Test Laboratories Inc.

  2. About Heart test Laboratories • HTL is a Texas based Company • HTL was established in 2007 • HTL has developed and released its“patent pending” MyoVista™, a portable diagnostic device for the screening of Myocardial Ischemia (MI)

  3. About Beaufort Medical • Beaufort Medical is a Dubai based Company • Beaufort Medical was established in 2005 • Beaufort Medical provides a range of services including the distribution of medical devices in the MENA region including the distribution of the MyoVista™ Diagnostic Device

  4. About Cardiovascular Disease

  5. About Cardiovascular Disease • According to the WHO, “Coronary Heart Disease is the leading cause of death worldwide” • It is on the rise and has become a true pandemic that respects no borders • 1 in 3 adults over the age of 40 have one or more types of cardiovascular disease

  6. About Myocardial Ischemia • 67% of all cardiovascular disease is correlated to some degree of Myocardial Ischemia • 75% of these patients with Myocardial Ischemiado not have any symptoms • “Silent Ischemia”

  7. Some Common Causes Leading to Heart Disease • Congenital heart defects & artery diseases • High blood pressure • Diabetes • Smoking & Drug Abuse • Excessive use of alcohol or caffeine • Stress • Some OTC/Prescription medications & Dietary supplements and herbal remedies

  8. Some Common Causes Leading to Heart Disease • Congenital heart defects & artery diseases • High blood pressure • Diabetes • Smoking & Drug Abuse • Excessive use of alcohol or caffeine • Stress • Some OTC/Prescription medications & Dietary supplements and herbal remedies

  9. Early Detection is the Key • Early diagnosis of CAD condition is critical • CAD is common and deadly • CAD is treatable if detected early

  10. Early Detection is the Key (Cont’d) • 75% of CAD patients do not have any symptoms • 50% of men and 64% of women who died suddenly of heart attacks had no previous symptoms • 1 in 3 patients are diagnosed after a heart attack occurs

  11. About Cardiovascular Disease in UAE

  12. About Cardiovascular Disease in UAE, MOH • Dr Ali Ahmad Bin Shakar, a senior Ministry of Health official in the UAE, stated that 41% of deaths in the UAE are caused by cardiovascular diseases. • He warned that forecasts for the next two decades predict a tripling of deaths from strokes and coronary heart disease in the Middle East and North Africa, a rate that exceeds any other region apart from Latin America.

  13. About Cardiovascular Disease in UAE, DOH • Dr. Azan Binbrek of Cardiology Department at Rashid Hospital in Dubai claimed that there was lack of medical research in the UAE because the general movement of people due to temporary nature of jobs. “We should play an active role in the community by promoting health awareness about diseases and their prevention, such as cardiovascular diseases”

  14. About Cardiovascular Disease in UAE, DOH • According to Dr Obaid Al Jassim, Consultant and Head of the Cardiothoracic Surgery Department with DHA, one in two deaths in the UAE are caused by cardiovascular diseases and that the first cardio event (strike) occurs at around 45, which is 10 to 15 years earlier than the international average of 55 to 60. • About 15,000 patients walk into Dubai government hospitals every year because of heart problems

  15. About Cardiovascular Disease in UAE, HAAD • Dr Michael Khouri, Cardiologist at Khalifa Hospital (HAAD), stated that the statistics are alarming, and reflects on the general lack of awareness of the risk factors of cardiovascular diseases including diabetes, hypertension, cholesterol, smoking and wrong lifestyles.Nearly 20 per cent of the heart patients were unaware that they had diabetes or hypertension or high cholesterol, thus exposing them to cardiovascular diseases.

  16. About Cardiovascular Disease in UAE, HAAD • Dr Cother Hajat, ex-section head, public health, stated that there are some alarming numbers on cardio-vascular diseases among Emiratis, which could be preventable by a rate of 90 per cent. 71 per cent of the young Emirati population [~ age 35], have at least one CVD risk factor. HAAD figures showed that 44 per cent of Emiratis have evidence of either pre-diabetes or diabetes, which has resulted in 750 heart attacks/mortality rates, each year among a young Emirati population.

  17. Current Devices Diagnosis Technology

  18. About Current Devices Diagnosis Technology • Current ECG machines have a 35% correlation to an invasive angiogram when identifying Myocardial Ischemia, thus missing approximately 65% of ischemic patients • Stress-ECG has a 50% correlation to an invasive angiogram when identifying Myocardial Ischemia

  19. About Current Devices Diagnosis Technology (Cont’d) • Angiograms, CAT Scans, and MRI’s are subjective to the human eyes • Angiograms, CAT Scans, and MRI’s are invasive and combine higher risks • Angiograms, CAT Scans, and MRI’s procedures are expensive

  20. About HTL MyoVista™ Technology

  21. About HTL MyoVista™ Technology • HTL MyoVista™ technology incorporates 3 dimensional mapping of the heart through proprietary algorithms that continuously multiplex each of the ten surface electrodes at 1000-8000Hz • The obtained data includes the Amplitude, timing and Spatial Relationship (frequency) of these signals

  22. About HTL MyoVista™ Technology • The current ECG technology processes approximately 1000 signals from the heart per second. HTL MyoVista™ technology processes 1 to 2 million signals from the Myocardium per second in a continuous manner • HTL MyoVista™ technology further analyze the signals with the help of additional pattern recognition software of 50,000 cardiac patients in the MyoVista database

  23. About HTL MyoVista™ Technology (Cont’d) • The current ECG machines have a 35% correlation to an invasive angiogram when identifying Myocardial Ischemia missing approximately 65% of ischemic patients • HTL MyoVista studies has shown over 89% correlation to an invasive angiogram when identifying Myocardial abnormalities-Ischemia

  24. About HTL MyoVista™ Technology (Cont’d) • Heart Test Laboratories Inc. is a CE approved product • Heart Test Laboratories Inc. has submitted all FDA required documentations • FDA approval of MyoVista™ Technology has been positioned on the fast track and expected soon

  25. About HTL MyoVista™ Technology (Cont’d)

  26. About HTL MyoVista™ Technology (Cont’d) No abnormality detected Suggests additional evaluation Color represents energy Lack of color represents a Lack of energy

  27. Benefits of Using the MyoVista™ Technology

  28. Benefits of Using the MyoVista™ Technology • The MyoVista™ Technology has high accuracy in the Identification for Myocardial Ischemia • The MyoVista™ Technology is fast Non-Invasive Procedure, (5-10 minutes for complete test) • The MyoVista™ Technology is a low cost procedure, thus producing a significant saving for both the patient and the healthcare system

  29. Benefits of Using the MyoVista™ Technology (Cont’d) • The MyoVista™ Technology is useful, reliable and powerful tool to aid in the diagnosis of CAD • The MyoVista™ Technology detect injuries caused by the obstruction of small coronary arteries which may not be detected by an ECG , stress test ECG or nuclear ECG • Easy to read so any care giver may administer

  30. Benefits of Using the MyoVista™ Technology (Cont’d) • The MyoVista™ Technology could be used in clinics, hospitals, ERs and doctors offices or any environment where patients are being evaluated for cardiovascular health • The MyoVista™ Technology could also be used in Pre and Post-operative evaluation of cardiac function in surgical patients

  31. Benefits of Using the MyoVista™ Technology (Cont’d) • The MyoVista™ Technology lower the overall costs to the healthcare system in the detection and prevention of coronary artery diseases • In addition to reducing the risk to public safety, The MyoVista™ Technology could be also useful for military personnel, industrial staff, pilots, etc.

  32. MyoVista™ Technology Cost Benefit Analysis • Current costs of Myocardial Ischemia screening • ECG  AED 200 ~ 400 • Stress ECG  AED 1,000 ~ 2,000 • Nuclear ECG  AED 3,000 ~ 4,000 • Angiogram  AED 8,000 ~ 10,000 • Total procedure cost  AED 12,200 ~ 16,400 • The MyoVista™ Technology cost less than AED 500

  33. MyoVista™ Technology Cost Benefit Analysis • Screening lead to prevention • Diagnosis lead to treatment • MyoVista™ Technology lead to preserving life one beat at a time

  34. Thank you

More Related